Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Intellia Therapeutics Inc (NASDAQ: NTLA) closed the day trading at $20.44 up 8.96% from the previous closing price of $18.76. In other words, the price has increased by $8.96 from its previous closing price. On the day, 7.79 million shares were traded. NTLA stock price reached its highest trading level at $20.585 during the session, while it also had its lowest trading level at $18.92.
Ratios:
For a better understanding of NTLA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.19 and its Current Ratio is at 5.19. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.11.
On March 05, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
JP Morgan Downgraded its Overweight to Neutral on February 28, 2025, whereas the target price for the stock was revised from $45 to $13.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 20 ’25 when CHASE WILLIAM J bought 100,000 shares for $10.03 per share. The transaction valued at 1,003,000 led to the insider holds 134,693 shares of the business.
Dulac Edward J III sold 7,462 shares of NTLA for $104,617 on Jul 23 ’25. The EVP, Chief Financial Officer now owns 106,062 shares after completing the transaction at $14.02 per share. On Jul 01 ’25, another insider, Clark Eliana, who serves as the EVP, Chief Technical Officer of the company, sold 1,022 shares for $9.82 each. As a result, the insider received 10,036 and left with 95,369 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 2194170368 and an Enterprise Value of 1837110400. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.51 while its Price-to-Book (P/B) ratio in mrq is 3.01. Its current Enterprise Value per Revenue stands at 34.756 whereas that against EBITDA is -3.661.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.46, which has changed by 0.13618672 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $21.47, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is 59.88%, while the 200-Day Moving Average is calculated to be 95.64%.
Shares Statistics:
Over the past 3-months, NTLA traded about 5.24M shares per day on average, while over the past 10 days, NTLA traded about 7489420 shares per day. A total of 105.33M shares are outstanding, with a floating share count of 101.56M. Insiders hold about 5.40% of the company’s shares, while institutions hold 87.86% stake in the company. Shares short for NTLA as of 1757894400 were 34137856 with a Short Ratio of 6.52, compared to 1755216000 on 27729214. Therefore, it implies a Short% of Shares Outstanding of 34137856 and a Short% of Float of 36.020002.
Earnings Estimates
Intellia Therapeutics Inc (NTLA) is currently under the scrutiny of 20.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.98, with high estimates of $0.04 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$2.67 and -$4.74 for the fiscal current year, implying an average EPS of -$4.11. EPS for the following year is -$4.01, with 23.0 analysts recommending between -$2.37 and -$5.05.
Revenue Estimates
A total of 24 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $210M, while the lowest revenue estimate was $30.87M, resulting in an average revenue estimate of $61.91M. In the same quarter a year ago, actual revenue was $57.88M
